

**Remarks/Arguments**

The provided restriction requirement divided the claims based on the presence of an aluminum phosphate-based adjuvant (Group I, claims 2-26), or the presence of a calcium phosphate-based adjuvant (Group II, claims 26-40). Claim 1 was indicated to be a linking claim for Groups I and II. In addition, a species election was provided with respect to the presence of antigens associated with a particular disease or disorder.


Applicants provisionally elect Group I (claims 2-26) and the species HIV. Linking claim 1 and Group I claims 2-8, 11, 12, 15-26 read on the elected species. Group II claims 27, 28, 30, 32, 33, 35, 36, 38 and 39 read on the elected species. The election is made without traverse.

The present amendment amends the priority claim to reference prior application 09/950,844, filed September 12, 2001, update the status of the prior applications, and indicate "claims benefit" in reference to a prior provisional application. The Transmittal Sheet submitted with the filing of the present application, and the filing receipt provided by the patent office, both reference prior application 09/950,844. Thus, it is believed that no petition under 37 CFR 1.78 and no surcharge under 36 CFR 1.17(t), are due in connection with the present amendment to the priority claim. (See, Manual of Patent Examining Procedure, Rev. 3, August 2005, Section 2.01.11 D, at page 200-64 section column.)

Serial No.: 10/764,921  
Case No.: 19907YIACB

Accordingly the claims are in condition for allowance. Please charge deposit account 13-2755 for fees due in connection with this amendment. If any time extensions are needed for the timely filing of the present amendment, applicants petition for such extensions and authorize the charging of deposit account 13-2755 for the appropriate fees.

Respectfully submitted,

By   
Sheldon O. Heber  
Reg. No. 38,179  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-1958